Medicare payments for sleep testing increased by $173 million from 2001 to 2009.
Sleep labs might be overutilized when it comes to testing for and diagnosing obstructive sleep apnea (OSA), and plans are paying the price.
AIM Specialty Health, a specialty benefit management company, recently launched its sleep management program, which aims to improve the clinical appropriateness and cost-effectiveness of diagnostic testing and ongoing therapy services for OSA. Parent company, WellPoint, Inc., is implementing the program with its affiliated health plans in 13 states.
The integrated program includes a clinical appropriateness review, a provider assessment allowing plans to evaluate providers based on quality and cost measures, as well as member engagement and therapy compliance monitoring.
“Comprehensive sleep programs ensure that patients get the most appropriate care, in the highest value setting,” says Brandon Cady, CEO, AIM Specialty Management. “These programs also improve patient engagement to sleep therapy and result in reduced costs for members, health plans and employers. ”
Without closely tracking compliance, health plans might be paying for unused equipment and supplies. When compared to home testing, there is a significant cost to the healthcare system. In fact, Medicare payments for sleep testing increased by $173 million from 2001 to 2009, according to the Office of the Inspector General. On the other hand, home testing accounts for only 1% to 3% of sleep study volume, although experts agree that it can be just as effective as lab testing at one-fifth the cost.
By collecting information directly from sleep testing and durable medical equipment vendors, providers, health plans and their members can make more informed decisions regarding care.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
A Renewed Commitment to HIV Vaccine Development Despite Advancements in Antiretrovirals | AIDS 2024
July 25th 2024The HIV vaccine field has recently faced setbacks with trials like PrepVacc, Mosaico and Imbokodo ending early due to lack of preventive efficacy. Although there have been challenges, scientists have made discoveries showing that the immune system can be prepared to fight HIV with special antibodies.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
ViiV Healthcare Will Not Continue Trials of Subcutaneous Cabenuva | AIDS 2024
July 25th 2024A substudy of the FLAIR phase 3 trial found that participants favored intramuscular injection of Cabenuva over the subcutaneous version due to pain and the development of nodules and reddening of the skin.
Read More